CEO of Beigene (30-Year Financial, Insider Trades) John Oyler (insider trades) sold 61,042 shares of BGNE on 09/02/2020 at an average price of $233.21 a share. The total sale was $14.2 million.
BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $21.58 billion; its shares were traded at around $234.94 with and P/S ratio of 70.68. GuruFocus has detected 5 severe warning signs with BeiGene Ltd. .
CEO Recent Trades:
- CEO John Oyler sold 61,042 shares of BGNE stock on 09/02/2020 at the average price of $233.21. The price of the stock has increased by 0.74% since.
- CEO John Oyler sold 92,177 shares of BGNE stock on 08/21/2020 at the average price of $237.06. The price of the stock has decreased by 0.89% since.
- CEO John Oyler sold 42,968 shares of BGNE stock on 08/14/2020 at the average price of $212.71. The price of the stock has increased by 10.45% since.
- CEO John Oyler sold 17,254 shares of BGNE stock on 08/05/2020 at the average price of $223.27. The price of the stock has increased by 5.23% since.
- CEO John Oyler sold 40,559 shares of BGNE stock on 08/04/2020 at the average price of $221.27. The price of the stock has increased by 6.18% since.
Directors and Officers Recent Trades:
- CMO, Hematology Jane Huang sold 3,000 shares of BGNE stock on 08/28/2020 at the average price of $242.21. The price of the stock has decreased by 3% since.
- Director Timothy Yung-cheng Chen sold 7,000 shares of BGNE stock on 08/12/2020 at the average price of $212.92. The price of the stock has increased by 10.34% since.
- Chair, Scientific Advisory Brd Xiaodong Wang sold 4,000 shares of BGNE stock on 08/10/2020 at the average price of $211.06. The price of the stock has increased by 11.31% since.
For the complete insider trading history of BGNE, click here
.
